Related Experiment Video

Updated: Jun 26, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Pharmacogenomics and analogues of the antitumour agent N6-isopentenyladenosine

Francesca Colombo1, F Stefania Falvella, Loris De Cecco

  • 1Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

International Journal of Cancer
|January 7, 2009
PubMed

Insights

N(6)-isopentenyladenosine (i(6)A), a cytokinin, shows in vitro anticancer effects by regulating cell cycle genes. However, its in vivo efficacy is limited, necessitating further research for potential therapeutic applications.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • N(6)-isopentenyladenosine (i(6)A) is a cytokinin with demonstrated in vitro anticancer properties.
  • Cytokinins are plant hormones known for their roles in growth and development.
  • Epithelial cancers represent a significant area of unmet medical need.

Purpose of the Study:

  • To investigate the in vitro and in vivo antitumour activity of N(6)-isopentenyladenosine (i(6)A).
  • To explore the structural requirements for i(6)A's anticancer effects.
  • To analyze the molecular mechanisms underlying i(6)A's impact on cancer cells.

Main Methods:

  • In vitro cell culture assays using human epithelial cancer cell lines.
  • Gene expression profiling to identify molecular targets of i(6)A.
  • Synthesis and evaluation of i(6)A analogues with structural modifications.
  • In vivo studies in mouse models to assess therapeutic efficacy.

Main Results:

  • i(6)A exhibited potent in vitro antitumour activity against human epithelial cancer cells.
  • Gene expression analysis revealed i(6)A induces genes involved in cell cycle arrest and stress response.
  • Only i(6)A with a saturated isopentenyl side chain retained in vitro activity, indicating structure-activity relationships.
  • Neither i(6)A nor its active analogue showed significant cancer cell growth inhibition in vivo.

Conclusions:

  • i(6)A demonstrates potential as an anticancer agent through cell cycle regulation in vitro.
  • The structural integrity of the isopentenyl side chain is crucial for i(6)A's biological activity.
  • Current analogues of i(6)A lack sufficient in vivo efficacy for therapeutic use.
  • Further research is required to develop potent and effective in vivo anticancer analogues of i(6)A.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...